1 Safety Monitoring of Medicinal Products. Guidelines for setting up and running a Pharmacovigilance Centre. Uppsala Monitoring Centre - WHO Collaborating Centre for International Drug Monitoring, EQUUS, London, 2000.
2 Lazarou J. et al., 1998. Incidence of ADR in hospitalized patients: a meta-analysis of prospective studies. JAMA, 1998, 279 (15) 1000-5.
3 Moore N et al. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 1998, 45(3), 301-308.
4 Imbs JL et al. Latrogenic medication: estimation of its prevalence in French public hospitals. Thèrapie, 1999, 54(1) 21-27.
5 Griffin GP. The evaluation of human medicines control from a national to an international perspective. Ad Drug React Toxico Rev., 1998, 17(1), 19-50.
6 White T et al. Counting the cost of drug-related adverse events. Pharmacoeconomics, 1999,15(5). 445-458.
7 Strom BL. Pharmacoepidemiology. 2nd ed. Chichester: John Wiley, 1994.
8 Venulet J. The Drug Monitoring Programme. In: Drug Surveillance, Geneva 1994, 13-21.
Section: Quality Assurance and Safety: Medicines
WHO Collaborating Centre for International Drug Monitoring (Uppsala Monitoring Centre)